Forte Biosciences, Inc. (FBRX)
NASDAQ · Healthcare
$47.49-2.80%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $509.61M
- P/E ratio
- —
- EPS
- —
- Volume
- 602,219
- 52-week high
- —
- 52-week low
- —
- Open
- $48.29
- Day high
- $52.15
- Day low
- $47.38
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$69.38M | -$4.71 |
| 2024 | — | -$35.48M | -$12.17 |
| 2023 | — | -$31.48M | -$24.92 |
| 2022 | — | -$13.88M | -$0.80 |
| 2021 | — | -$21.71M | -$1.55 |
About Forte Biosciences, Inc.
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
- CEO
- Paul A. Wagner
- Employees
- 22
- Country
- US
- IPO date
- Apr 13, 2017
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Forte Biosciences, Inc.'s stock price today?
- FBRX is trading at $47.49 as of Jul 20, 2026.
- What is Forte Biosciences, Inc.'s market cap?
- Forte Biosciences, Inc. (FBRX) has a market capitalization of $509.61M.
- Does Forte Biosciences, Inc. pay a dividend?
- Forte Biosciences, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Forte Biosciences, Inc. in?
- Forte Biosciences, Inc. operates in the Healthcare sector.